Resultado de búsqueda
30 de nov. de 2015 · β-Blockers are less effective in reducing central than peripheral systolic blood pressure. This effect is less pronounced with vasodilating than with nonvasodilating β-blockers, although the difference is mostly explained by a lower reduction in heart rate with the former.
22 de abr. de 2015 · Abstract. Cardiometabolic risk describes a collection of risk factors, with a likely underlying pathophysiology, resulting in accelerated atherosclerosis and the terminal cardiovascular events of myocardial infarction and stroke. Beta-blockers, which are divided as vasodilators or non-vasodilators, are used in the treatment of ...
5 de may. de 2020 · Importantly, beta-blockers are a heterogeneous class. Whilst vasodilating beta-blockers, such as nebivolol, have demonstrated favourable effects on central BP and cardiovascular surrogates, RCTs with these newer beta-blockers in hypertensive patients are currently lacking.
9 de jun. de 2021 · Nebivolol has additional vasodilator actions, related to enhanced release of NO in the vascular wall. In principle, this additional mechanism compared with bisoprolol might lead to more potent vasodilatation, which in turn might influence the effectiveness of nebivolol in the management of HFrEF, IHD and hypertension.
Abstract. β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure (cSBP) as compared with peripheral SBP (pSBP). Whether this effect is less pronounced with vasodilating β-blockers (VBB) when compared with nonvasodilating β-blockers (NVBB) remains unsettled.
Beta-blockers, which are divided as vasodilators or non-vasodilators, are used in the treatment of hypertension and other cardiovascular diseases. Vasodilators have been shown to be of particular benefit in both blood pressure control and other cardiometa-bolic components with limited disturbance in metabolic pa-rameters.
11 de may. de 2023 · The pathophysiology of hypertension suggest that non vasodilating β-blockers are preferred, as first-line, in young/middle aged hypertensive patients (< 60 years), to decrease sympathetic hyperactivity and consequently high BP, while vasodilating b-blockers, are most appropriate, as first choice, in elderly patients (> 60 years ...
